7[7]Arikian SR, Casciano J, Doyle JJ, et al. A pharmacoeconomic evaluation of two new products for the treatment ofoveractive bladder[J]. Monag Care Inte rface ,2000,13(2) :88.
8[8]Hill RP, Lubarsky DA, Phillips BB, et al. Cost-effectiveness of prophylactic antiemetic therapy with ondansetron, droperidol, or placebo [J]. Anesthesiology,2000,92(4) :958.
9[10]McCoy S, Blayney-Chandramouli J, Mutnick A. Using multiple pharmacoeconomic methods to condut a cost-effectiveness analysis of histamine H2-receptor antagonists[J]. Am J Health Syst Pharm, 1998, 55(Suppl 4):s8.
10[16]Schumacher GE. Multiattribute evaluation in formulary decision making as applied to calcium-channel blockers[J] .Am J Hosp Pharm,1991,48(2):301.
